A NEW PROMISING STRATEGY ISLET MACROCELL ENCAPSULATION DEVICE IN THE TREATMENT OF TYPE I DIABETES
Kasireddy Naga Kalyani Durga*, Swetha Mohan K., Purushothama Reddy K. and Kantamaneni Padmalatha
Islet transplantation can treat the foremost severe cases of type I diabetes (TID), but it currently requires deceased donor pancreatic as an islet source and chronic immunosuppression to forestall rejection and recurrence of autoimmunity. Stem cell derived insulin-producing cells can overcome the shortage of organ donors, while cell encapsulation can reduce or eliminate the necessity for immunosuppression, reduce the risks related to with the islet transplantation process and potentially prolonged can survive. A range of materials are used to test for microencapsulation in various animal models and a few materials were shown to induce immunosuppression in islet grafts without the necessity for chronic immunosuppression. Despite the initial success of microcapsules within the NHP model, the combined use of islet transplantation and microencapsulation has not yet been successful in clinical trials.
Keywords: Type I diabetes (TID), Immunosuppression, Microencapsulation, Islet transplantation.
[Full Text Article]